Adverse drug reactions caused by statins, with emphasis on psychiatric reactions. Data from the spontaneous reporting system;Statiner - bivirkningsmonster med vekt pa psykiske reaksjoner. Data fra nasjonal og internasjonal database

Tidsskrift for den Norske Laegeforening

Volumn 117, Issue 22, 1997, Pages 3210-3213

  Buajordet, Ingebjørg ^a   Madsen, Steinar ^a,c   Olsen, Harald ^b,c  

^a Medisinsk Avdeling   (Norway)

^b Psykiatrisk Klinikk Vinderen   (Norway)

^c Bærum Sykehus ^*  (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; HYPOCHOLESTEROLEMIC AGENT;

ANXIETY NEUROSIS; ARTICLE; CASE REPORT; DEPRESSION; HUMAN; IMPOTENCE; MENTAL DISEASE; MYOPATHY; NERVOUSNESS; NEUROTOXICITY; SLEEP DISORDER; ADULT; AGED; CHEMICALLY INDUCED DISORDER; DRUG SURVEILLANCE PROGRAM; DRUG UTILIZATION; FACTUAL DATABASE; FEMALE; MALE; MIDDLE AGED; NORWAY; WORLD HEALTH ORGANIZATION;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; ANTICHOLESTEREMIC AGENTS; DATABASES, FACTUAL; DRUG UTILIZATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MENTAL DISORDERS; MIDDLE AGED; NORWAY; WORLD HEALTH ORGANIZATION;

EID: 0031580631     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Pedersen TR, Tobert JA. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease. A reappraisal. Drug Saf 1996; 1: 11-24.
2. Henwood JM, Heel RC. Lovastatin. A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia. Drugs 1988; 36: 429-54.
3. London SF, Gross KF, Ringel SP. Cholesterol-lowering agent myopathy. Neurology 1991; 41: 1159-60.
4. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
5. Shepherd J, Cobbe SM, Ford I, Isles CG, Lormier AR, Macfarlarne PW et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7.
6. The WOSCOPS Study Group. Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. Am J Cardiol 1995; 76: 485-91.
7. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.
8. Edwards IR, Biriell C. Harmonisation in pharmacovigilance. Drug Saf 1994; 10: 93-102.
9. Strom B. Pharmacoepidemiology: Response to the Callenge. Pharmacoepidemiology and Drug Safety 1995; 4: 11-4.
10. Waller PC, Wood SM, Langman MJS, Breckenridge AM, Rawlins MD. Review of company postmarketing surveillance studies. BMJ 1992; 304: 1470-2.
11. WHO International Drug Monitoring Program. Report Tyep-A, 31. December 1995. Genève: WHO Collaborating Centre for International Drug Monitoring, 1995.
12. Edwards IR. International drug monitoring. I: Aronson JK, van Boxtel CJ, red. Side effects of drugs. Annual 18. Amsterdam: Elsevier, 1995: 468-77.
13. Legemiddelforbruk i Norge 1988-92. Oslo: Norsk Medisinaldepot, 1993: 74.
14. Legemiddelforbruk i Norge 1991-1995. Oslo: Norsk Medisinaldepot, 1996: 80.
15. Garnett WR. The pharmacology of fluvastatin, a new HMG-CoA rcductase inhibitor. Clin Cardiol 1994; 17 (suppl IV): IV3-IV10.
16. Felleskatalog over farmasøytiske spesial-preparater markedsført i Norge 1996/97. Oslo: Felleskatalogen AS, 1996.
17. Shepherd J. Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety. Eur Heart J 1995; 16: 5-13.
18. Aursnes I. Drugs affecting lipid metabolisme. I: Dukes MNG, red. Meyler's side effects of drugs. Amsterdam: Elsevier, 1992: 1097-106.
19. Laaksonen R, Ojala J-P, Tikkanen MJ, Himberg J-J. Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1994; 46: 313-7.
20. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990; 264: 71-5.
21. Wallace CS, Mueller BA. Lovastatin-induced rhabdomyolysis in the absence of concomitant drugs. Ann Parmacother 1992; 26: 190-2.
22. Pedersen TR, Berg K. Cook TJ, Færgeman O, Haghfelt T, Kjekshus J et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1996; 156: 2085-92.
23. Wardle J, Armitage J, Collins R, Wallendszus K, Keech A, Lawson A et al. Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration. BMJ 1996; 313: 75-8.
24. Santanello NC, Barber BL, Applegate WB, Elam J, Curtis C, Hunninghake DB et al. Effect of pharmacologic lipid lowering on health-related quality of life in older persons: results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study. J Am Geriatr Soc 1997; 45: 8-14.
25. Boccuzzi SJ, Bocanegra TS, Walker JF, Shapiro DR, Keegan ME. Long-term safety and efficacy profile of simvastatin. Am J Cardiol 1991; 68: 1127-31.
26. Rosenson RS, Goranson NL. Lovastatin-associated sleep and mood disturbances. Am J Med 1993; 95: 548-9.
27. Zureik M, Courbon D, Ducimetiere P. Serum cholesterol concentration and death from suicide in men: Paris prospective study I. BMJ 1996; 313: 649-51.
28. Ploeckinger B, Dantendorfer K, Ulm M, Baischer W, Derfler K, Musalek M et al. Rapid decrease of serum cholesterol concentration and postpartum depression. BMJ 1996; 313: 664-79.
29. Adverse Drug Reactions Advisory Committee. Simvastatin and adverse endocrine effects in men. Australian Adverse Drug Reactions Bulletin 1995; 14: 10.
30. Boyd IW. Comment: HMG-CoA reductase inhibitor-induced impotence. Ann Pharmacother 1996; 30: 1199.
31. Bruckert E, Giral P, Heshmati HM, Turpin G. Men treated with hypolipidaemic drugs complain more frequently of erectil dysfunction. Journal of Clinical Pharmacy and Therapeutics 1996; 21: 89-94.
32. Halkin A. HMG-CoA reductase inhibitor-induced impotence. Ann Pharmacother 1996; 30: 192.